SETT ATT FRAMSTELLA 3,4-DISUBSTITUERADE 2-(BETA-NAFTYL-OXI)-ETYLPYRAZOLONER OCH ANVENDNING DERAV SOM LEKEMEDEL
Pyrazolones of formula (I) are novel cpds. including the tautomeric forms. (where R1 = H, CF3 or alkyl, aryl, aralkyl or heteroaryl each of which may be substd; R2 = opt. substd. alkyl, aryl, aralkyl, trihalomethyl-mercapto, alkoxy or aryloxy; R3 = naphthyl which may be substd. by 1-3 groups chosen...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Patent |
| Sprache: | swe |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | H HORSTMANN F SEUTER K-A MENG E MOLLER |
| description | Pyrazolones of formula (I) are novel cpds. including the tautomeric forms. (where R1 = H, CF3 or alkyl, aryl, aralkyl or heteroaryl each of which may be substd; R2 = opt. substd. alkyl, aryl, aralkyl, trihalomethyl-mercapto, alkoxy or aryloxy; R3 = naphthyl which may be substd. by 1-3 groups chosen from halo, CF3, alkyl alkenyl, alkoxy, alkylamino, cyano, CF3O-, nitro, hydroxy, -SOn-alkyl or -SOn-CF3 and n = 0-2). (I) are antithrombotic cpds. which may be administered orally or parenterally for therapeutic or prophylactic treatment of thrombo-embolic disorders, blood clots etc. Pref. daily doses are 0.1-10 mg/kf parenterally or 0.5-100 mg/kg orally, formulated by usual methods. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_SE7613536A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>SE7613536A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_SE7613536A3</originalsourceid><addsrcrecordid>eNqFi7EOgjAURVkcjPoNvlETOyiK84M-tLG0pn0QcSHE1MkgCf5_ZHB3uDlnOHcadZ6YAcflDgvPpDVCvNkLqXyZelZckkNJsBOrlBiFwZxrLexNrQWNdq0d3q22hhzY7AxoKjLSKHMCOT4r8LYATRcqSJKeR5Nn-xrC4sdZtMyJs7MI_bsJQ98-Qhc-jadjso0PcYLx_-ILdvg2YQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>SETT ATT FRAMSTELLA 3,4-DISUBSTITUERADE 2-(BETA-NAFTYL-OXI)-ETYLPYRAZOLONER OCH ANVENDNING DERAV SOM LEKEMEDEL</title><source>esp@cenet</source><creator>H HORSTMANN ; F SEUTER ; K-A MENG ; E MOLLER</creator><creatorcontrib>H HORSTMANN ; F SEUTER ; K-A MENG ; E MOLLER</creatorcontrib><description>Pyrazolones of formula (I) are novel cpds. including the tautomeric forms. (where R1 = H, CF3 or alkyl, aryl, aralkyl or heteroaryl each of which may be substd; R2 = opt. substd. alkyl, aryl, aralkyl, trihalomethyl-mercapto, alkoxy or aryloxy; R3 = naphthyl which may be substd. by 1-3 groups chosen from halo, CF3, alkyl alkenyl, alkoxy, alkylamino, cyano, CF3O-, nitro, hydroxy, -SOn-alkyl or -SOn-CF3 and n = 0-2). (I) are antithrombotic cpds. which may be administered orally or parenterally for therapeutic or prophylactic treatment of thrombo-embolic disorders, blood clots etc. Pref. daily doses are 0.1-10 mg/kf parenterally or 0.5-100 mg/kg orally, formulated by usual methods.</description><language>swe</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>1977</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=19770606&DB=EPODOC&CC=SE&NR=7613536A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76289</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=19770606&DB=EPODOC&CC=SE&NR=7613536A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>H HORSTMANN</creatorcontrib><creatorcontrib>F SEUTER</creatorcontrib><creatorcontrib>K-A MENG</creatorcontrib><creatorcontrib>E MOLLER</creatorcontrib><title>SETT ATT FRAMSTELLA 3,4-DISUBSTITUERADE 2-(BETA-NAFTYL-OXI)-ETYLPYRAZOLONER OCH ANVENDNING DERAV SOM LEKEMEDEL</title><description>Pyrazolones of formula (I) are novel cpds. including the tautomeric forms. (where R1 = H, CF3 or alkyl, aryl, aralkyl or heteroaryl each of which may be substd; R2 = opt. substd. alkyl, aryl, aralkyl, trihalomethyl-mercapto, alkoxy or aryloxy; R3 = naphthyl which may be substd. by 1-3 groups chosen from halo, CF3, alkyl alkenyl, alkoxy, alkylamino, cyano, CF3O-, nitro, hydroxy, -SOn-alkyl or -SOn-CF3 and n = 0-2). (I) are antithrombotic cpds. which may be administered orally or parenterally for therapeutic or prophylactic treatment of thrombo-embolic disorders, blood clots etc. Pref. daily doses are 0.1-10 mg/kf parenterally or 0.5-100 mg/kg orally, formulated by usual methods.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>1977</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqFi7EOgjAURVkcjPoNvlETOyiK84M-tLG0pn0QcSHE1MkgCf5_ZHB3uDlnOHcadZ6YAcflDgvPpDVCvNkLqXyZelZckkNJsBOrlBiFwZxrLexNrQWNdq0d3q22hhzY7AxoKjLSKHMCOT4r8LYATRcqSJKeR5Nn-xrC4sdZtMyJs7MI_bsJQ98-Qhc-jadjso0PcYLx_-ILdvg2YQ</recordid><startdate>19770606</startdate><enddate>19770606</enddate><creator>H HORSTMANN</creator><creator>F SEUTER</creator><creator>K-A MENG</creator><creator>E MOLLER</creator><scope>EVB</scope></search><sort><creationdate>19770606</creationdate><title>SETT ATT FRAMSTELLA 3,4-DISUBSTITUERADE 2-(BETA-NAFTYL-OXI)-ETYLPYRAZOLONER OCH ANVENDNING DERAV SOM LEKEMEDEL</title><author>H HORSTMANN ; F SEUTER ; K-A MENG ; E MOLLER</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_SE7613536A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>swe</language><creationdate>1977</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>H HORSTMANN</creatorcontrib><creatorcontrib>F SEUTER</creatorcontrib><creatorcontrib>K-A MENG</creatorcontrib><creatorcontrib>E MOLLER</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>H HORSTMANN</au><au>F SEUTER</au><au>K-A MENG</au><au>E MOLLER</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>SETT ATT FRAMSTELLA 3,4-DISUBSTITUERADE 2-(BETA-NAFTYL-OXI)-ETYLPYRAZOLONER OCH ANVENDNING DERAV SOM LEKEMEDEL</title><date>1977-06-06</date><risdate>1977</risdate><abstract>Pyrazolones of formula (I) are novel cpds. including the tautomeric forms. (where R1 = H, CF3 or alkyl, aryl, aralkyl or heteroaryl each of which may be substd; R2 = opt. substd. alkyl, aryl, aralkyl, trihalomethyl-mercapto, alkoxy or aryloxy; R3 = naphthyl which may be substd. by 1-3 groups chosen from halo, CF3, alkyl alkenyl, alkoxy, alkylamino, cyano, CF3O-, nitro, hydroxy, -SOn-alkyl or -SOn-CF3 and n = 0-2). (I) are antithrombotic cpds. which may be administered orally or parenterally for therapeutic or prophylactic treatment of thrombo-embolic disorders, blood clots etc. Pref. daily doses are 0.1-10 mg/kf parenterally or 0.5-100 mg/kg orally, formulated by usual methods.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | swe |
| recordid | cdi_epo_espacenet_SE7613536A |
| source | esp@cenet |
| subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | SETT ATT FRAMSTELLA 3,4-DISUBSTITUERADE 2-(BETA-NAFTYL-OXI)-ETYLPYRAZOLONER OCH ANVENDNING DERAV SOM LEKEMEDEL |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T09%3A22%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=H%20HORSTMANN&rft.date=1977-06-06&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ESE7613536A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |